Filtros de búsqueda

Lista de obras de

(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.

artículo científico publicado en 2007

111InBz-DTPA-hEGF: Preparation andIn VitroCharacterization of a Potential Anti-Glioblastoma Targeting Agent ⬇️

artículo científico publicado el 1 de agosto de 2003

188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.

artículo científico publicado en 2014

99mTc(CO)3+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours ⬇️

artículo científico publicado el 21 de noviembre de 2012

99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

artículo científico publicado en 2007

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.

artículo científico publicado en 2010

ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers

artículo científico publicado en 2015

Affibody Molecules as Targeting Vectors for PET Imaging

scientific article published on 11 March 2020

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors

artículo científico publicado en 2018

Affibody-mediated PET imaging of HER3 expression in malignant tumours.

artículo científico publicado en 2015

Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.

artículo científico publicado en 2006

Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377

artículo científico publicado en 2018

Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides.

artículo científico publicado en 2003

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules

scientific article published on 13 March 2020

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.

artículo científico publicado en 2016

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer

scientific article published on 14 September 2019

Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution

scientific article published on 01 May 1999

Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.

artículo científico publicado en 2016

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA.

artículo científico publicado en 2017

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

artículo científico publicado en 2018

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties

scientific article published on 08 February 2019

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibod

artículo científico publicado en 2011

Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.

artículo científico publicado en 2015

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts

artículo científico publicado en 2019

Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours

artículo científico publicado en 2018

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts ⬇️

artículo científico publicado el 30 de noviembre de 2011

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m

artículo científico publicado en 2017

Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2

scientific article published on 11 February 2019

Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression

artículo científico publicado en 2017

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands

artículo científico publicado en 2022

Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.

artículo científico publicado en 2009

Detecting ligand interactions with G protein-coupled receptors in real-time on living cells.

artículo científico publicado en 2013

Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.

artículo científico publicado en 2008

Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution

artículo científico publicado en 2014

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.

artículo científico publicado en 2018

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

scientific article published on 30 December 2020

Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.

artículo científico publicado en 2008

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model

artículo científico publicado en 2020

Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.

artículo científico publicado en 2005

Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

artículo científico publicado en 2014

Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.

artículo científico publicado en 2018

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart

artículo científico publicado en 2019

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus

artículo científico publicado en 2012

Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules

artículo científico publicado en 2008

Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules

scientific article published on 12 April 2011

Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression

artículo científico publicado en 2017

Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.

artículo científico publicado en 2013

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab

artículo científico publicado en 2018

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors

artículo científico publicado en 2016

Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.

artículo científico publicado en 2015

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1

artículo científico publicado en 2020

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.

scientific article published on 05 October 2016

Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo

artículo científico publicado en 2014

HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.

artículo científico publicado en 2013

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

artículo científico publicado en 2010

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution

artículo científico publicado en 2020

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model

scientific article published on 01 July 2020

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.

artículo científico publicado en 2017

Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes

artículo científico publicado en 2014

Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.

artículo científico publicado en 2011

Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients.

artículo científico publicado en 2014

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

artículo científico publicado en 2006

Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.

artículo científico publicado en 2014

Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.

artículo científico publicado en 2011

Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.

artículo científico publicado en 2014

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake

scientific article published on 01 May 2019

In Vivo and In Vitro Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors ⬇️

artículo científico publicado el 5 de marzo de 2013

In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging

artículo científico publicado en 2013

In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.

artículo científico publicado en 2005

In vitro modeling of HER2-targeting therapy in disseminated prostate cancer.

artículo científico publicado en 2014

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.

artículo científico publicado en 2017

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates

scientific article published on 14 August 2019

Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.

artículo científico publicado en 2013

Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules

artículo científico publicado en 2019

Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules

artículo científico publicado en 2016

Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging

scientific article published on 21 June 2019

Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.

artículo científico publicado en 2012

Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins

artículo científico publicado en 2016

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs

artículo científico publicado en 2018

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules

artículo científico publicado en 2020

Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

artículo científico publicado en 2011

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.

artículo científico publicado en 2018

Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets.

artículo científico publicado en 2010

Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts

artículo científico publicado en 2013

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin

artículo científico publicado en 2016

Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.

artículo científico publicado en 2013

Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.

artículo científico publicado en 2016

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.

artículo científico publicado en 2008

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification

artículo científico publicado en 2013

Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design ⬇️

artículo científico publicado el 8 de julio de 2012

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

artículo científico publicado en 2013

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

artículo científico publicado en 2016

Methods for radiolabelling of monoclonal antibodies

artículo científico publicado en 2014

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of Ga-Labeled Tracers ⬇️

artículo científico publicado en 2019

Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties

scientific article published on 14 February 2011

Molecular design of radiocopper-labelled Affibody molecules.

artículo científico publicado en 2018

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

artículo científico publicado en 2010

On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

artículo científico publicado en 2009

Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3

artículo científico publicado en 2019

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

artículo científico publicado en 2010

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111

artículo científico publicado en 2019

Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga

scientific article published on 20 June 2018

Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.

artículo científico publicado en 2011

PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.

artículo científico publicado en 2016

Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.

artículo científico publicado en 2014

Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.

artículo científico publicado en 2009

Preclinical Evaluation of [Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors

artículo científico publicado en 2018

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer

artículo científico publicado en 2020

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer

artículo científico publicado en 2020

Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line

artículo científico publicado en 2011

Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer. Influence of Labeling Chemistry on Targeting Properties

artículo científico publicado en 2020

Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.

artículo científico publicado en 2014

Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

artículo científico publicado en 2010

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1

artículo científico publicado en 2020

Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label

artículo científico publicado en 2017

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model

artículo científico publicado en 2018

Radionuclide therapy of HER2-expressing human xenografts using an affibody molecule-based PNA-mediated pretargeting: in vivo proof-of-principle

artículo científico publicado en 2018

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.

artículo científico publicado en 2007

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology

artículo científico publicado en 2018

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.

artículo científico publicado en 2014

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26

artículo científico publicado en 2019

Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.

artículo científico publicado en 2016

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6

scientific article published on 10 May 2019

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity

artículo científico publicado en 2015

Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting

artículo científico publicado en 2019

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

artículo científico publicado en 2013

Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.

artículo científico publicado en 2008

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer

artículo científico publicado en 2019

Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.

artículo científico publicado en 2013

Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.

artículo científico publicado en 2009

Synthesis of 11C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [11C]CO.

artículo científico publicado en 2016

Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

artículo científico publicado en 2007

Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.

artículo científico publicado en 2010

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

artículo científico publicado en 2009

The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.

artículo científico publicado en 2014

The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.

artículo científico publicado en 2014

The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.

artículo científico publicado en 2009

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.

artículo científico publicado en 2017

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

artículo científico publicado en 2019

Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.

artículo científico publicado en 2012

Update: affibody molecules for molecular imaging and therapy for cancer.

artículo científico publicado en 2007

Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.

artículo científico publicado en 2011

[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.

artículo científico publicado en 2004

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda